Approval · Notice of Compliance 5964 · 1994
CAPOZIDE: Notice of Compliance 5964
Issued May 24, 1994
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 5964
- Date
- May 24, 1994
- Company
- Squibb Canada Inc., Division Of Bristol-Myers Squibb Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New dosage regimen
- Therapeutic class
- Angiotensin converting enzyme inhibitor, diuretic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CAPOZIDE | Not yet assigned | — |
Medicinal ingredients
- HYDROCHLOROTHIAZIDE 25 MG per TAB
- CAPTOPRIL 25 MG per TAB
- HYDROCHLOROTHIAZIDE 12.5 MG per TAB
- CAPTOPRIL 50 MG per TAB